Literature DB >> 31359219

Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models.

Theodoros Papathanasiou1,2, Anders Strathe3, Rune Viig Overgaard3, Trine Meldgaard Lund4, Andrew C Hooker5.   

Abstract

Combinations of pharmacological treatments are increasingly being investigated for potentially higher clinical benefit, especially when the combined drugs are expected to act via synergistic interactions. The clinical development of combination treatments is particularly challenging, particularly during the dose-selection phase, where a vast range of possible combination doses exists. The purpose of this work was to evaluate the added value of using optimal design for guiding the dose allocation in drug combination dose-finding studies as compared with a typical drug-combination trial. Optimizations were performed using local [D(s)-optimality] and global [ED(s)-optimality] optimal designs to maximize the precision of model parameters in a number of potential exposure-response (E-R) surfaces. A compound criterion [D(s)/V-optimality] was used to optimize the precision of model predictions in specific parts of the E-R surfaces. Optimal designs provided unbiased estimates and significantly improved the accuracy of results relative to the typical design. It was possible to improve the efficiency and overall parameter precision up to 7832% and 96.6% respectively. When the compound criterion was used, the probability to accurately identify the optimal dose-combination increased from 71% for the typical design up to 91%. These results indicate that optimal design methodology in tandem with E-R analyses is a beneficial tool that can be used for appropriate dose allocation in dose-finding studies for drug combinations.

Keywords:  Dose allocation; Drug combinations; Exposure-response analyses; Optimal design; Response surface

Year:  2019        PMID: 31359219     DOI: 10.1208/s12248-019-0365-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  26 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool.

Authors:  Joakim Nyberg; Sebastian Ueckert; Eric A Strömberg; Stefanie Hennig; Mats O Karlsson; Andrew C Hooker
Journal:  Comput Methods Programs Biomed       Date:  2012-05-27       Impact factor: 5.428

Review 3.  Multi-target therapeutics: when the whole is greater than the sum of the parts.

Authors:  Grant R Zimmermann; Joseph Lehár; Curtis T Keith
Journal:  Drug Discov Today       Date:  2006-11-28       Impact factor: 7.851

4.  Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment.

Authors:  Matts Kågedal; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-03-20       Impact factor: 2.745

5.  Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Authors:  Philippe B Pierrillas; Sylvain Fouliard; Marylore Chenel; Andrew C Hooker; Lena E Friberg; Mats O Karlsson
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

Review 6.  Current pharmacotherapy for obesity.

Authors:  Gitanjali Srivastava; Caroline M Apovian
Journal:  Nat Rev Endocrinol       Date:  2017-10-13       Impact factor: 43.330

Review 7.  Pharmacotherapy of type 2 diabetes: An update.

Authors:  Jagriti Upadhyay; Stergios A Polyzos; Nikolaos Perakakis; Bindiya Thakkar; Stavroula A Paschou; Niki Katsiki; Patricia Underwood; Kyung-Hee Park; Jochen Seufert; Eun Seok Kang; Elliot Sternthal; Asterios Karagiannis; Christos S Mantzoros
Journal:  Metabolism       Date:  2017-09-08       Impact factor: 8.694

8.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.

Authors:  R J Keizer; M O Karlsson; A Hooker
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-26

9.  Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).

Authors:  F T Musuamba; E Manolis; N Holford; Sya Cheung; L E Friberg; K Ogungbenro; M Posch; Jwt Yates; S Berry; N Thomas; S Corriol-Rohou; B Bornkamp; F Bretz; A C Hooker; P H Van der Graaf; J F Standing; J Hay; S Cole; V Gigante; K Karlsson; T Dumortier; N Benda; F Serone; S Das; A Brochot; F Ehmann; R Hemmings; I Skottheim Rusten
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-19

10.  Confidence and Prediction Intervals for Pharmacometric Models.

Authors:  Anne Kümmel; Peter L Bonate; Jasper Dingemanse; Andreas Krause
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-03-25
View more
  2 in total

1.  Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis.

Authors:  Asbjørn Nøhr-Nielsen; Theis Lange; Julie Lyng Forman; Theodoros Papathanasiou; David J R Foster; Richard N Upton; Ole Jannik Bjerrum; Trine Meldgaard Lund
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

2.  Pharmacometrics meets statistics-A synergy for modern drug development.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Elin M Svensson; Grace Montepiedra; Andrew C Hooker; Weng Kee Wong
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.